Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5 | $9 | $7 | $15 |
| G&A Expenses | $3 | $2 | $3 | $0 |
| SG&A Expenses | $3 | $2 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $10 | $10 | $17 |
| Operating Income | -$8 | -$10 | -$10 | -$17 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $1 |
| Pre-Tax Income | -$8 | -$10 | -$10 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$10 | -$10 | -$16 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.16 | -0.17 | -0.27 |
| % Growth | 18.8% | 5.9% | 37% | – |
| EPS Diluted | -0.13 | -0.16 | -0.17 | -0.27 |
| Weighted Avg Shares Out | 60 | 60 | 60 | 59 |
| Weighted Avg Shares Out Dil | 60 | 60 | 60 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$9 | -$9 | -$15 |
| % Margin | – | – | – | – |